Prevalence of Acquired Carbapenemase Genes in *Klebsiella Pneumoniae* by Multiplex PCR in Isfahan

**Abstract**

**Background:** Multi-drug resistant *Klebsiella pneumoniae* has been considered as a serious global threat. This study was done to investigate carbapenemase producing genomes among *K. pneumoniae* isolates in Isfahan, Central Iran. **Materials and Methods:** In a cross-sectional study from 2011 to 2012, 29 carbapenem resistant (according to disc diffusion method) carbapenemase producing (according to modified Hodge test) *K. pneumoniae* strains were collected from Intensive Care Unit (ICUs) of Al-Zahra referral Hospital. In the strains with the lack of sensitivity to one or several carbapenems, beta-lactams, or beta-lactamases, there has been performed modified Hodge test to investigate carbapenemase and then only strains producing carbapenemases were selected for molecular methods. **Results:** In this study, there have been 29 cases of *K. pneumoniae* isolated from hospitalized patients in the (ICU). Three cases (10.3%) contained blaVIM, 1 case (3.4%) contained blaIMP, and 1 case (3.4%) contained blaOXA. The genes blaNDM and blaKPC were not detected. Then, 16 cases (55.2%) from positive cases of *K. pneumoniae* were related to the chip, 4 cases (13.8%) to catheter, 6 cases (20.7%) to urine, and 3 cases (10.3%) to wound. **Conclusion:** It is necessary to monitor the epidemiologic changes of these carbapenemase genes in *K. pneumoniae* in our Hospital. More attention should be paid to nosocomial infection control measures. Other carbapenemase producing genes should be investigated.

**Keywords:** Carbapenemase, imipenemas, *Klebsiella pneumoniae*, Klebsiella pneumoniae carbapenemase, New Delhi metslb-b-lactamase, oxacillinase, Verona integrion-encoded metallo-b-lactamase

**Introduction**

The emergence of carbapenemase producing *Enterobacteriaceae* is of concern because for which, very few (if any) antibiotic alternatives remain available. This is the reason why early detection of carbapenemase producers is significant.[1] On the other hand, in some cases, despite microbial resistance, there is no increase in minimum inhibitory concentration of carbapenems, and so using molecular techniques and not only phenotypic tests are very helpful to decrease mortality, morbidity, and treatment costs.[2]

Understanding the background of genetic mechanisms information of resistance to antibiotics can facilitate the ways of prevention, control, and limitation of the infectious diseases. This can be easily performed using polymerase chain reaction (PCR) molecular methods with high reliability. It is necessary to use PCR molecular methods to prove the conclusive existence of carbapenemase genomes. In fact, PCR molecular methods are the standard techniques to identify carbapenemases.[3][4]

According to a study of Poirel et al.[3] in 2011, multiplex PCR methods are as suitable as simplex PCR methods to screen productive genes of carbapenemases, and these methods are considered as the rapid and trustworthy methods (<4 h).

In geographical areas that the carbapenemase producing organisms are not endemic, all dominant genes can produce resistance and it is necessary to consider multiplex PCR methods as the first screening method. Also, this method is suitable in epidemiological studies and is an economical method.[5]

*Klebsiella pneumoniae* is an opportunistic pathogen from the family *Enterobacteriaceae* capable to cause carbapenem resistant infections in hospitals.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

---

**How to cite this article:** Khorvash F, Yazdani MR, Soudi AA, Shabani S, Tavahen N. Prevalence of Acquired Carbapenemase Genes in *Klebsiella Pneumoniae* by Multiplex PCR in Isfahan. Adv Biomed Res 2017;6:41.

**Received:** February, 2015. **Accepted:** July, 2015.
especially Intensive Care Units (ICUs). The investigation of the studies has shown that the most common genes producing carbapenemases in *K. pneumoniae* are derived from five genes *K. pneumoniae* carbapenemase (KPC), imipenemase (IMP), Verona integron-encoded metallo-b-lactamase (VIM), oxacillinase (OXA), and New Delhi metslb-b-lactamase (NDM).[6]

Due to phenotypic methods, there are several reports on the appearance of *K. pneumoniae* resistant to carbapenems obtained from the patients hospitalized in ICUs in Al-Zahra referral Hospital of Isfahan University of Medical Sciences. The purpose of this study is to investigate the prevalence of KPC, IMP, VIM, OXA, and NDM genes in *K. pneumoniae* isolates in Al-Zahra Hospital. Also, due to limited financial resources, there is not possible to investigate other genes in this study.

This study can be helpful in providing initial information on the prevalence of the nosocomial infections by *K. pneumoniae* producing carbapenemases in order to monitor and control the drug resistances and codify suitable policies for the identification and control of the nosocomial infections and planning principles to physicians and health administrations.

**Materials and Methods**

This is a cross-sectional study, conducted in Al-Zahra referral Hospital, Isfahan in 2011–2012. The protocol was approved by the Medical Ethics Committee of Isfahan University of Medical Sciences.

Twenty-nine carbapenemase producing *K. pneumoniae* specimens were collected from the ICUs of Al-Zahra Hospital of Isfahan University of Medical Sciences. The clinical sources of the specimens included blood, urine, sputum, and wound secretions.

The diagnosis of *Klebsiella* was performed using the colony morphology. Susceptibility profile was identified by Kirby–Bauer disc diffusion method as recommended by Clinical and Laboratory Standards Institute (CLSI). The modified Hodge test also was performed to endorse the existence of carbapenemase enzymes according to CLSI recommendations and only carbapenemases producing strains were selected for molecular methods.

In all samples, DNA was extracted using of phenol-chloroform method and five pair primers blaKPC, blaVIM, blaIMP, blaNDM, and blaOXA with the sizes 232–798 bp and one pair primer blaSHV-1 for the initial control and the confirmation of *K. pneumoniae* (made by Metabion Company, Germany) was purchased in the form of lyophilization [Table 1]. Amplification was performed using thermocycler T-CY (Netherland). Every cycle includes denaturation DNA at 94°C for 10 min and then other amplification includes 30 cycles at 94°C for 20 s, 40 cycles at 52°C for 40 s and final extension at 72°C for 5 min. After third stage and final stage of the amplification, the product was stained on an agarose gel (2%), and analyzed with ethidum bromide in voltage 100 for an hour with electrophoresis set (made by Paya Pajoohesh, Pars Company, Iran), and then the multiplied genes were separated due to their molecular weight. Finally, the separated genes were observed and recorded the composed images in the detector and recording gel set (UVI doc). Also, detection of genes was compared with positive control.

**Results**

In this study, there have been 29 cases of *K. pneumoniae* isolated from hospitalized patients in the ICU. The mean ages of the patients were 53.6 ± 18.2 in the range of 20–78 years. Among them, 20 patients were male (69%), and 9 patients were female (31%). The mean age of women and men was 50.4 ± 20.2 and 60.6 ± 10.5 years, respectively, and there was no significant difference between the genders ($P = 0.17$).

As shown in Table 2, the gene expression was shown based on patients age, sex, and source of sample. According to this table, no statistically difference between fore groups based above variables.

The investigation of blaKPC, blaIMP, blaVIM, blaOXA, and blaNDM genes showed that 5 cases (17.2%) from

| Primer (bp) | Sequence (5'-3') | Gene | Product size |
|------------|----------------|------|-------------|
| IMP-F      | GGAATAGAGTGCTTAAYTCTC | blaIMP | 232         |
| IMP-R      | GGTTTAAAYAAACAACCACCC | blaIMP | 390         |
| VIM-F      | GATGGTGTTTGGTGCATA | blaVIM | 390         |
| VIM-R      | CGAATTGCAGCACCAG | blaVIM | 438         |
| OXA-F      | GCCGTCGTTAAGGATGAACAC | blaOXA | 798         |
| OXA-R      | CATCAATTCAACCAACCAG | blaOXA | 232         |
| KPC-Fm     | CGTGCTATCCTGTGTCATGAGGC | blaKPC | 621         |
| KPC-Rm     | CTTGTCATCCTGTGTCATGAGGC | blaKPC | 798         |
| NDM-F      | GGTTTGGGCATCGGTTTCTTTC | blaNDM | 798         |
| NDM-R      | CGGAATGGCCTCATCAGCATC | blaNDM | 232         |

KPC: *Klebsiella pneumoniae* carbapenemase, IMP: Imipenemase, VIM: Verona integron-encoded metallo-b-lactamase, OXA: Oxacillinase, NDM: New Delhi metslb-b-lactamase, PCR: Polymerase chain reaction
Khorvash, et al.: Carbapenemase genes in Klebsiella pneumoniae

29 cases contain one of these genes. Three cases (10.3%) contained blaVIM, 1 case (3.4%) contained blaIMP, and 1 case (3.4%) contained blaOXA (P < 0.05). The genes blaNDM and blaKPC were not detected (P < 0.05) [Figure 1].

Then, 16 cases (55.2%) from positive cases of K. pneumoniae were related to the chip, 4 cases (13.8%) to catheter, 6 cases (20.7%) to urine, and 3 cases (10.3%) to wound. Due to these results, the greatest resistance was to ampicillin and meropenem compared to imipenem so that each case from 29 cases (100%) were resistant to these antibiotics. Also, 28 samples (6.96%) were resistant to ceftazidime, ciprofloxacin, and cefotaxime, and 1 case (3.4%) was susceptible to these three antibiotics. Also, 27 cases (93.1%) were resistant to cefepime, and 23 samples (3.70%) were resistant to amikacin. The only antibiotic affected on these strains effectively was colistin, so that all 29 samples were susceptible to it [Figure 2].

Discussion

The increasing prevalence of multi-drug resistant K. pneumoniae isolates has been associated with higher morbidity and mortality rates. The overall purpose of this study is to investigate the prevalence of blaKPC, blaIMP, blaVIM, blaOXA, and blaNDM genes in K. pneumoniae by multiplex PCR molecular method in isolated specimens from patients admitted in ICUs in Al-Zahra Hospital during 2011–2012.

The blaKPC is the most common carbapenemase in the United States.[7] Several reports described hospital outbreaks in the North-eastern United States involving K. pneumoniae carrying KPC.[8,9] KPC-harboring isolates have also been increasingly recovered from other parts of the world, including Europe,[10] Asia,[11,12] and South America.[13] KPC producing K. pneumoniae isolates have been reported from Tehran, Iran.[14]

The blaNDM has been reported from India, Pakistan, and other parts of Asia, Europe, North America, and Australia.[15,16] In 2013, Shahcheraghi et al., reported first case of NDM-producing K. pneumoniae in Tehran, Iran.[17]

In our study, the blaKPC and blaNDM were not identified so far, because of rapid progression rates of these genes, it is necessary to monitor the epidemiologic changes of these carbapenemase genes in K. pneumonia in our hospital. One study[18] reported high frequency of blaKPC gene in K. pneumonia in Al-Zahra Hospital, but they used nonmolecular methods and genes can only be detected by molecular methods.

The blaVIM and blaIMP genes have been described in Asia, Europe, North America, South America, and Australia.[19,20] According to a study of Zeighami et al. in 2015 in Zanjan, Iran, metallo-b-lactamase producing K. pneumoniae strains carried blaIMP and blaVIM were found in 100% and 41.6%, respectively.[21]

The blaOXA was identified in Turkey, Europe, the Middle East, and Northern Africa.[22] In 2013, Azimi et al., reported first case of OXA-producing K. pneumoniae in Iran (Azimi).

In our study, blaIMP, blaVIM, and blaOXA were identified in the minority (17.2%) of samples. Thus, other carbapenemase producing genes should be investigated.

It is suggested that further studies with more samples should be considered to investigate the existence of genes

| Table 2: Gene expression base on demographic data |
|-----------------------------|-----------------|-------------|----------|-----------------|------|
| Genes variables            | Negative        | VIM         | IMP      | OXA   | P         |
| Mean of age (year)         | 55.9±17.2       | 53±20.7     | 25       | 28    | 0.19      |
| Sex, n (%)                 |                 |             |          |       |           |
| Male                       | 17 (70.8)       | 1 (33.3)    | 1 (100)  | 1 (100) | 0.65     |
| Female                     | 7 (29.2)        | 2 (66.7)    | 0 (0)    | 0 (0)  |           |
| Source of samples, n (%)   |                 |             |          |       |           |
| Trachea                    | 13 (54.2)       | 2 (66.7)    | 0 (0)    | 1 (100) | 0.6      |
| Catheter                   | 4 (16.7)        | 0 (0)       | 0 (0)    | 0 (0)  |           |
| Urine                      | 5 (20.8)        | 1 (33.3)    | 0 (0)    | 0 (0)  |           |
| Wound                      | 2 (8.3)         | 0 (0)       | 1 (100)  | 1 (100) |           |

IMP: Imipenemase, VIM: Verona integron-encoded metallo-b-lactamase, OXA: Oxacillinase

![Figure 1: Frequency distribution of genes expression in 29 cases of Klebsiella pneumoniae](image1)

![Figure 2: Frequency distribution of antibiotic resistance of Klebsiella pneumoniae samples](image2)
containing carbapenemases. By recognition of resistant organisms and prescribing suitable antibiotics, we can decrease the mortality and morbidity of hospitalized patients in ICUs and minimize the costs and duration of hospitalization.

In order to existence of blaIMP, blaVIM, and blaOXA genes in *K. pneumoniae* in our hospital and possibility of horizontal transmission to other bacteria, more attention should be paid to nosocomial infection control measures.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Poirel L, Pitout JD, Nordmann P. Carbapenemases: Molecular diversity and clinical consequences. Future Microbiol 2007;2:501-12.
2. Borger A, Saidel-Odes L, Riesenber K, Eskira S, Peled N, Nativ R, et al. Attributable mortality rate for carbapenem-resistant *Klebsiella pneumoniae* bacteremia. Infect Control Hosp Epidemiol 2009;30:972-6.
3. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 2011;70:119-23.
4. Cuzon G, Ouanich J, Gondret R, Naas T, Nordmann P. Outbreak of OXA-48-positive carbapenem-resistant *Klebsiella pneumoniae* isolates in France. Antimicrob Agents Chemother 2011;55:2420-3.
5. Patel JB, Rasheed JK, Kitchel B. Carbapenemases in *Enterobacteriaceae*: Activity, epidemiology and laboratory detection. Clin Microbiol NewsL 2009;31:55-62.
6. Centers for Disease Control and Prevention (CDC). Vital signs: Carbapenem-resistant *Enterobacteriaceae*. MMWR Morb Mortal Wkly Rep 2013;62:165-70.
7. Won SY, Munoz-Price LS, Lolans K, Hota B, Weinstein RA, Hayden MK, et al. Emergence and rapid regional spread of *Klebsiella pneumoniae* carbapenemase-producing *Enterobacteriaceae*. Clin Infect Dis 2011;53:532-40.
8. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant *Klebsiella pneumoniae* in New York city: A new threat to our antibiotic armamentarium. Arch Intern Med 2005;165:1430-5.
9. Marquez P, Terashita D, Dassey D, Mascola L. Population-based incidence of carbapenem-resistant *Klebsiella pneumoniae* along the continuum of care, Los Angeles county. Infect Control Hosp Epidemiol 2013;34:144-50.
10. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a *Klebsiella pneumoniae* isolate from France. Antimicrob Agents Chemother 2005;49:4423-4.
11. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant *Klebsiella pneumoniae* strains in an Israeli hospital. Antimicrob Agents Chemother 2007;51:3026-9.
12. Wei ZQ, Du XX, Yu YS, Shen P, Chen YG, Li LJ. Plasmid-mediated KPC-2 in a *Klebsiella pneumoniae* strain. Antimicrob Agents Chemother 2007;51:763-5.
13. Villegas MV, Lolans K, Correa A, Suarez CJ, Lopez JA, Vallejo M, et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of *Klebsiella pneumoniae* from South America. Antimicrob Agents Chemother 2006;50:2880-2.
14. Rastegar Lari A, Azimi L, Rahbar M, Fallah F, Alaghehbandan R. Phenotypic detection of *Klebsiella pneumoniae* carbapenemase among burns patients: First report from Iran. Burns 2013;39:174-6.
15. Sidjabat H, Nimmo GR, Walsh TR, Binotto E, Htin A, Hayashi Y, et al. Carbapenem resistance in *Klebsiella pneumoniae* due to the New Delhi metallo-beta-lactamase. Clin Infect Dis 2011;52:481-4.
16. Centers for Disease Control and Prevention (CDC). Carbapenem-resistant *Enterobacteriaceae* containing New Delhi metallo-beta-lactamase in two patients – Rhode Island, March 2012. MMWR Morb Mortal Wkly Rep 2012;61:446-8.
17. Shahcheraghi F, Nobari S, Rahmati Ghezelgeh F, Nasiri S, Owlia P, Nikkin VS, et al. First report of New Delhi metallo-beta-lactamase-1-producing *Klebsiella pneumoniae* in Iran. Microb Drug Resist 2013;19:30-6.
18. Moayedenia R, Shokri D, Mobasherizadeh S, Baradaran A, Fatemi SM, Merrikhi A. Frequency assessment of beta-lactamase enzymes in *Escherichia coli* and *Klebsiella* isolates in patients with urinary tract infection. J Res Med Sci 2014;19 Suppl 1:541-5.
19. Crespo MP, Woodford N, Sinclair A, Kaufmann ME, Turton J, Glover J, et al. Outbreak of carbapenem-resistant *Pseudomonas aeruginosa* producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004;42:509-14.
20. Peleg AY, Franklin C, Bell J, Spelman DW. Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia. J Antimicrob Chemother 2004;54:609-700.
21. Zeighami H, Hagh F, Hajiahmadi F. Molecular characterization of integrons in clinical isolates of betalactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in Iran. J Chemother 2015;27:145-51.
22. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing *Enterobacteriaceae*. Emerg Infect Dis 2011;17:1791-8.